RAReem Amine

Reem Amine

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Reem Amine has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Differential Visual Outcomes in Neovascular AMD Based on Ellipsoid Zone Integrity and Fluid Presence: Insights from a Phase III Trial

    by Justis P. Ehlers, Sari Yordi, Hasan Cetin, Reem Amine, Karen Matar, Asmita Indurkar, Katherine E. Talcott, Peter K. Kaiser, Arshad M. Khanani, Joanne Hu, et al.

    Background/Objectives: To investigate the effect of ellipsoid zone (EZ) integrity and retinal fluid on best-corrected visual acuity (BCVA) in neovascular, age-related macular degeneration. Methods: This was a post hoc treatment-agnostic analysis of the phase 3 HAWK trial. Intraretinal fluid (IRF), subretinal fluid (SRF), and ellipsoid zone (EZ) integrity were quantified over 48 weeks. EZ integrity maintenance was defined as EZ-RPE central subfield thickness (CST) >20 µm; partial EZ attenuation was EZ-RPE CST >0 and ≤20 µm; total EZ attenuation was EZ-RPE CST = 0 µm. Results: During treatment, BCVA in eyes with no fluid (66.5 to 70.2 letters) was greater than in eyes with IRF (59.5 to 62.4 letters) but comparable to BCVA in eyes with SRF (64.9 to 68.8 letters). In eyes with no fluid, BCVA was consistently greater in eyes with EZ integrity maintained (73.4 to 78.4 letters) than in eyes with EZ partial attenuation (65.3 to 66.5 letters) or with EZ total attenuation (55.8 to 59.8 letters). Conclusions: Eyes without fluid with EZ preservation achieved the highest overall BCVA, especially when compared to eyes without fluid and a lack of EZ preservation and to eyes with SRF. Achieving a “dry” status with preservation of EZ integrity is important in optimizing visual outcomes.


  • Open Access

    The Feasibility and Clinical Evaluation of an Immersive Augmented Reality Surgical Headset Integrated with Swept-Source Intraoperative Optical Coherence Tomography for Ophthalmic Surgery in the DISCOVER Study

    by Masaharu Mizuno, Karen Matar, Reem Amine, Katherine E. Talcott, Jeffrey M. Goshe, William J. Dupps, Sumit Sharma, Asmita Indurkar, John Mamone, Jamie Reese, et al.

    Objectives: to evaluate the feasibility and utility of intraoperative optical coherence tomography (iOCT) utilizing an immersive augmented reality surgical headset (Beyeonics iOCT, Beyeonics Vision Ltd., Haifa, Israel) digital visualization platform with swept-source integrated OCT in ophthalmic surgery. Methods: As part of the Institutional Review Board-approved prospective DISCOVER study, the Beyeonics iOCT was utilized in multiple ophthalmic surgical procedures to evaluate the feasibility and utility of iOCT with this platform. The Beyeonics iOCT is a three-dimensional surgical visualization system that utilizes a swept-source integrated OCT within the digital microscope system. Surgeon feedback on system performance and integration into the surgical workflow was gathered via a prespecified survey. Results: Thirteen eyes of thirteen patients were included in this study. The surgical procedures consisted of four cataract surgeries, two lamellar corneal transplants, one pterygium removal, and six vitreoretinal surgeries. Surgeons were able to successfully view and review the iOCT images within the surgical Head-Mounted Display, eliminating the need for an external display. Utility feedback from surgeons included iOCT assisting with confirming wound architecture, corneal graft orientation, and retinal structure. All surgeries were completed without reverting to a conventional microscope, and no intraoperative adverse events occurred. Conclusions: The new visualization platform with integrated swept-source iOCT demonstrated feasibility and potential utility in multiple ophthalmic surgical platforms. Additional research related to outcomes, ergonomics, and enhanced software analysis is needed in the future.